Open in web browser

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

Cancer drugs

Cancer drug: Are the high benefits worth the high risks?

By Christine Blank
Patients with previously-treated metastic colorectal cancer (mCRC) taking regorafenib (Stivarga) experienced progression-free survival of 2.7 months, according to new data presented at the recent ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona. Read more

Studies: Zykadia shrank tumors in patients with ALK+ NSCLC

By Tracey Walker
New data from two phase 2 studies showed ceritinib (Zykadia) shrank tumors in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who had received previous treatment with an ALK inhibitor and in those receiving an ALK inhibitor for the first time. Study details

CONTINUING EDUCATION

MTM essentials for COPD management: Part 1

This month's CE activity is part of a CPE series, Medication Therapy Management for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to assist pharmacists in understanding the pathophysiology and pharmacologic treatment of COPD and to discuss how COPD is similar to and different from other chronic respiratory disorders.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the Session Code: 15DT31-KTJ28.

The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php.
To review your registration page or to register, go to:
https://web2.uconn.edu/pharmacyce/program_register.php.
For a full list of courses, go to
http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Investigational drug reverses anticoagulant effect of dabigatran in minutes: Study

By Tracey Walker
Use of investigational reversal agent idarucizumab can allow physicians to focus on other vital aspects of emergency management beyond anticoagulant reversal in dabigatran-treated patients, according to a study published in the New England Journal of Medicine. Data details

July 17, 2015

Related Articles

ASCO set to compare value of cancer drugs

Drugs in Perspective: Zykadia (ceritinib)

Resources

Get the latest FormularyWatch updates on drug approvals, current studies, and other findings.

Click for the latest Clinical News

Click here to contact Editorial. Sales, Reprints, Classified questions? Click here to contact the Sales Team.

ModernMedicine logo
UBM  logo

UBM MEDICA